Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia.

O'Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Soc Administrative Pharm. 2015;11(3):e101-9. DOI: 10.1016/j.sapharm.2013.04.006. PubMed PMID: 23632161.

High dosage of aripiprazole-induced dysphagia.

Lin T-W, Lee B-S, Liao Y-C, Chiu N-Y, Hsu W-Y. High dosage of aripiprazole-induced dysphagia. Int. J. Eat. Disord. 2012;45(2):305-6. DOI: 10.1002/eat.20934. PubMed PMID: 21541978.

Paliperidone-induced dystonic Dysphagia.

Mendhekar DN, Agarwal A. Paliperidone-induced dystonic Dysphagia. JNP. 2010;22(4):451-v.e37-451.e37. DOI: 10.1176/appi.neuropsych.22.4.451-v.e37. PubMed PMID: 21037154.

Neuroleptic-induced dysphagia: case report and literature review.

Dziewas R, Warnecke T, Schnabel M, Ritter M, Nabavi DG, Schilling M, et al. Neuroleptic-induced dysphagia: case report and literature review. Dysphagia. 2007;22(1):63-7. DOI: 10.1007/s00455-006-9032-9. PubMed PMID: 17024549.

Antipsychotic drugs and risk of venous thromboembolism: nested case-control study.

Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245. DOI: 10.1136/bmj.c4245. PubMed PMID: 20858909.

Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients.

Malý R, Masopust J, Hosák L, Konupcíková K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62(1):3-8. DOI: 10.1111/j.1440-1819.2007.01773.x. PubMed PMID: 18289135.

The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.

Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211-20. DOI: 10.1111/ijcp.12752. PubMed PMID: 26477545.

Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.

Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, et al. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study. J Clin Psychopharmacol. 2016;36(6):597-607. DOI: 10.1097/JCP.0000000000000587. PubMed PMID: 27805978.

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.

Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, et al. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. J Clin Psychiatry. 2016;77(10):1381-1390. DOI: 10.4088/JCP.15m10490. PubMed PMID: 27788310.

A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer.

Bradford DW, Goulet J, Hunt M, Cunningham NC, Hoff R. A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer. J Clin Psychiatry. 2016;77(12):e1626-e1630. DOI: 10.4088/JCP.15m10281. PubMed PMID: 27780332.